Yervoy and Centrum silver drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Yervoy (ipilimumab) and Centrum silver (ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e). Common drug interactions include adverse drug reaction among females and pneumonia among males.

The phase IV clinical study analyzes what interactions people have when they take Yervoy and Centrum silver. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Yervoy?

Yervoy has active ingredients of ipilimumab. eHealthMe is studying from 26,662 Yervoy users. Check the latest studies of Yervoy.

What is Centrum silver?

Centrum silver has active ingredients of ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e. It is often used in vitamin supplementation. eHealthMe is studying from 19,997 Centrum silver users. Check the latest studies of Centrum silver.



On Jul, 27, 2026

14 people who take Yervoy and Centrum silver together, and have interactions are studied.

Yervoy and Centrum silver drug interactions.

What are the common drug interactions of Yervoy and Centrum Silver, by gender? *:

female:

  1. Adverse drug reaction
  2. Adverse event
  3. Enterocolitis haemorrhagic (bleeding and inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon)
  4. Herpes zoster
  5. Hypersensitivity

male:

  1. Pneumonia
  2. Diarrhoea
  3. Colitis (inflammation of colon)
  4. Decreased appetite
  5. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  6. Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
  7. Dyspnoea (difficult or laboured respiration)
  8. Haematochezia (passage of stools containing blood)
  9. Heart rate increased
  10. Hepatic failure (liver failure)

What are the common drug interactions of Yervoy and Centrum Silver, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Anaphylactoid reaction (type of anaphylaxis that does not involve an allergic reaction but is due to direct mast cell degranulation)
  2. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  3. Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults)
  4. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
  5. Klebsiella bacteraemia (klebsiella bacteria in blood after infection to lungs)
  6. Pneumonia
  7. Rash maculo-papular (red area on the skin that is covered with small confluent bumps)

60+:

  1. Diarrhoea
  2. Pneumonia
  3. Decreased appetite
  4. Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
  5. Dyspnoea (difficult or laboured respiration)
  6. Enterocolitis haemorrhagic (bleeding and inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon)
  7. Haematochezia (passage of stools containing blood)
  8. Heart rate increased
  9. Hepatic failure (liver failure)
  10. Hepatomegaly (abnormal enlargement of the liver)

What are the existing conditions these people have? *

  1. Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 4 people, 28.57%
  2. Malignant Melanoma (skin cancer rises from melancytes): 3 people, 21.43%
  3. Rhabdomyosarcoma (cancer of the bone, soft tissues, or connective tissue (e.g., tendon or cartilage)): 2 people, 14.29%
  4. Renal Cell Carcinoma (a kidney cancer): 2 people, 14.29%
  5. Prostate Cancer: 2 people, 14.29%
  6. Neoplasm Malignant (cancer tumour): 1 person, 7.14%
  7. Herpes Zoster: 1 person, 7.14%
  8. Haemolytic Uraemic Syndrome (blood clotting disease caused by e. coli infection, birth control pills, pneumonia, medications, and more): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Yervoy and Centrum silver?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Yervoy and Centrum silver:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Yervoy:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Centrum silver:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Yervoy and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Centrum silver and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ipilimumab and ascorbic acid; biotin; cyanocobalamin; dexpanthenol; ergocalciferol; folic acid; niacinamide; pyridoxine hydrochloride; riboflavin phosphate sodium; thiamine hydrochloride; vitamin a; vitamin e (the active ingredients of Yervoy and Centrum silver, respectively), and Yervoy and Centrum silver (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: